› Forums › General Melanoma Community › Keytruda and Opdivo
- This topic has 27 replies, 4 voices, and was last updated 8 years, 8 months ago by
jpg.
- Post
- Replies
-
-
- August 3, 2015 at 6:39 pm
There's a good answer to this question here: http://melanomainternational.org/2015/08/august-3-2015-ipianti-pd1-ocular-mucosal-vaccines/#.Vb-0uflViko
The two will never go head to head because of financial interests!
-
- August 3, 2015 at 6:39 pm
There's a good answer to this question here: http://melanomainternational.org/2015/08/august-3-2015-ipianti-pd1-ocular-mucosal-vaccines/#.Vb-0uflViko
The two will never go head to head because of financial interests!
-
- August 3, 2015 at 6:39 pm
There's a good answer to this question here: http://melanomainternational.org/2015/08/august-3-2015-ipianti-pd1-ocular-mucosal-vaccines/#.Vb-0uflViko
The two will never go head to head because of financial interests!
-
- August 3, 2015 at 8:05 pm
I progressed on keytruda but stayed on it 12 months. Then due to they ran out the day I was there I could either come back the next day or switch to opdivo. So I switched and was on it 2 months. Finally seeing another doc this week to try and get in their trial. I was on it although progressed some the whole time it really slowed the growth down a whole lot. I'll get a scan this week at the trial screening but I doubt if opdivo is any better than keytruda. However if we look deeper to the dosage and frequency the FDA approved there was a small trial arm of keytruda at that dose and frequency with a 25% response rate. Granted other arms with higher doses had responses in the 40ish%. I'm not sure about opdivo what the small response arms were at its FDA approved frequency and dose. But yes insurance approved that switch within a few minutes granted the reason was supply issues rather than progression issues. The doc said he's really not seen a difference in results but I'm his first that's been on both. As far as manufacturing there is a tiny difference in the human monoclonal antibody they are made from but it is really minor making them almost the same. Now other pd1s are made from different stuff so the response has been varied with those. Like one trial nobody responded. I feel so sorry for the folks that were in that and then excluded from other pd1 trials because they already had pd1.
Artie
-
- August 3, 2015 at 9:12 pm
The answer is there isn't to the doctor's knowledge a case where someone did better on opdivo vs. keytruda or vice versa. They are panning out to be the same but we will not see the clinical trial of one against the other.
Pretty much what Artie's doc said.
-
- August 3, 2015 at 9:36 pm
Oh ok. Not really looking for stats of one verses the other, but more of anyone's personal experience of trying Nivo after Keytruda or vice versa. In otherwords, do they work exactly the same or do they target different proteins allowing one to be successful for an individual over the other.
Thanks for your input Artie!
-
- August 3, 2015 at 9:36 pm
Oh ok. Not really looking for stats of one verses the other, but more of anyone's personal experience of trying Nivo after Keytruda or vice versa. In otherwords, do they work exactly the same or do they target different proteins allowing one to be successful for an individual over the other.
Thanks for your input Artie!
-
- August 3, 2015 at 9:36 pm
Oh ok. Not really looking for stats of one verses the other, but more of anyone's personal experience of trying Nivo after Keytruda or vice versa. In otherwords, do they work exactly the same or do they target different proteins allowing one to be successful for an individual over the other.
Thanks for your input Artie!
-
- August 3, 2015 at 9:12 pm
The answer is there isn't to the doctor's knowledge a case where someone did better on opdivo vs. keytruda or vice versa. They are panning out to be the same but we will not see the clinical trial of one against the other.
Pretty much what Artie's doc said.
-
- August 3, 2015 at 9:12 pm
The answer is there isn't to the doctor's knowledge a case where someone did better on opdivo vs. keytruda or vice versa. They are panning out to be the same but we will not see the clinical trial of one against the other.
Pretty much what Artie's doc said.
-
- August 3, 2015 at 8:05 pm
I progressed on keytruda but stayed on it 12 months. Then due to they ran out the day I was there I could either come back the next day or switch to opdivo. So I switched and was on it 2 months. Finally seeing another doc this week to try and get in their trial. I was on it although progressed some the whole time it really slowed the growth down a whole lot. I'll get a scan this week at the trial screening but I doubt if opdivo is any better than keytruda. However if we look deeper to the dosage and frequency the FDA approved there was a small trial arm of keytruda at that dose and frequency with a 25% response rate. Granted other arms with higher doses had responses in the 40ish%. I'm not sure about opdivo what the small response arms were at its FDA approved frequency and dose. But yes insurance approved that switch within a few minutes granted the reason was supply issues rather than progression issues. The doc said he's really not seen a difference in results but I'm his first that's been on both. As far as manufacturing there is a tiny difference in the human monoclonal antibody they are made from but it is really minor making them almost the same. Now other pd1s are made from different stuff so the response has been varied with those. Like one trial nobody responded. I feel so sorry for the folks that were in that and then excluded from other pd1 trials because they already had pd1.
Artie
-
- August 3, 2015 at 8:05 pm
I progressed on keytruda but stayed on it 12 months. Then due to they ran out the day I was there I could either come back the next day or switch to opdivo. So I switched and was on it 2 months. Finally seeing another doc this week to try and get in their trial. I was on it although progressed some the whole time it really slowed the growth down a whole lot. I'll get a scan this week at the trial screening but I doubt if opdivo is any better than keytruda. However if we look deeper to the dosage and frequency the FDA approved there was a small trial arm of keytruda at that dose and frequency with a 25% response rate. Granted other arms with higher doses had responses in the 40ish%. I'm not sure about opdivo what the small response arms were at its FDA approved frequency and dose. But yes insurance approved that switch within a few minutes granted the reason was supply issues rather than progression issues. The doc said he's really not seen a difference in results but I'm his first that's been on both. As far as manufacturing there is a tiny difference in the human monoclonal antibody they are made from but it is really minor making them almost the same. Now other pd1s are made from different stuff so the response has been varied with those. Like one trial nobody responded. I feel so sorry for the folks that were in that and then excluded from other pd1 trials because they already had pd1.
Artie
-
- August 3, 2015 at 10:33 pm
Raquel, I think that if a person stops responding to one of the Pd-1 drugs, the Oncologist would probably try to get the patient into one of the new trials for other Inhibitory pathways like Tim-3 or Lag-3 or one of the trials looking at Activatiing receptors like GITR or OX40. They might also be directed towards Adoptive T-cell therapy that Dr. Patrick Hwu at M.D. Anderson specializes in. Wishing you the best!!! Ed
-
- August 3, 2015 at 10:33 pm
Raquel, I think that if a person stops responding to one of the Pd-1 drugs, the Oncologist would probably try to get the patient into one of the new trials for other Inhibitory pathways like Tim-3 or Lag-3 or one of the trials looking at Activatiing receptors like GITR or OX40. They might also be directed towards Adoptive T-cell therapy that Dr. Patrick Hwu at M.D. Anderson specializes in. Wishing you the best!!! Ed
-
- August 4, 2015 at 12:39 pm
A personal experience isn't as important as a large group of people. And the companies will not do a trial of Pd1 vs. Pd1 probably. So going through a lot with insurance to switch from one to the other isn't probably worth the hassle. I did hear that if you do well on IPI you will do well on PD1 but not a big study on that either.
-
- August 4, 2015 at 12:39 pm
A personal experience isn't as important as a large group of people. And the companies will not do a trial of Pd1 vs. Pd1 probably. So going through a lot with insurance to switch from one to the other isn't probably worth the hassle. I did hear that if you do well on IPI you will do well on PD1 but not a big study on that either.
-
- August 4, 2015 at 1:50 pm
Luckily the scans came back as stable and maybe even a little regression so we can table the thought of switching anti PD-1 for now. Since there are no clinical trials comparing all I can go on are personal experiences. I Just wanted to point out that not everyone has access to clinical trials. She is disqualified from them so was just trying to look at options. And anything is worth the hassle to get her better, even insurance companies.
thanks to those for listening.
-
- August 4, 2015 at 1:50 pm
Luckily the scans came back as stable and maybe even a little regression so we can table the thought of switching anti PD-1 for now. Since there are no clinical trials comparing all I can go on are personal experiences. I Just wanted to point out that not everyone has access to clinical trials. She is disqualified from them so was just trying to look at options. And anything is worth the hassle to get her better, even insurance companies.
thanks to those for listening.
-
- August 4, 2015 at 1:50 pm
Luckily the scans came back as stable and maybe even a little regression so we can table the thought of switching anti PD-1 for now. Since there are no clinical trials comparing all I can go on are personal experiences. I Just wanted to point out that not everyone has access to clinical trials. She is disqualified from them so was just trying to look at options. And anything is worth the hassle to get her better, even insurance companies.
thanks to those for listening.
-
- August 4, 2015 at 12:39 pm
A personal experience isn't as important as a large group of people. And the companies will not do a trial of Pd1 vs. Pd1 probably. So going through a lot with insurance to switch from one to the other isn't probably worth the hassle. I did hear that if you do well on IPI you will do well on PD1 but not a big study on that either.
-
- August 3, 2015 at 10:33 pm
Raquel, I think that if a person stops responding to one of the Pd-1 drugs, the Oncologist would probably try to get the patient into one of the new trials for other Inhibitory pathways like Tim-3 or Lag-3 or one of the trials looking at Activatiing receptors like GITR or OX40. They might also be directed towards Adoptive T-cell therapy that Dr. Patrick Hwu at M.D. Anderson specializes in. Wishing you the best!!! Ed
-
- You must be logged in to reply to this topic.